Analytical Data
-
Gene name
EZH1
- Application
-
Alternative Names
KMT6B; ENX-2; Histone-lysine N-methyltransferase EZH1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q92800
-
Expression Region
Pro559~Leu747
-
Molecular Weight
25kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
EZH1, a member of the Polycomb Repressive Complex 2 (PRC2), plays a crucial role in gene regulation through its histone methyltransferase activity, specifically in tri-methylating lysine 27 of histone H3 (H3K27me3). This specific modification is essential for maintaining gene repression during developmental processes and cellular differentiation. Dysregulation of EZH1 has been implicated in various cancers, suggesting its pivotal role in tumorigenesis and the potential as a therapeutic target. In recent studies, researchers have focused on the structural characteristics and enzymatic mechanisms of EZH1, exploring how its activity is modulated by post-translational modifications and interactions with other proteins. Understanding the functional dynamics of EZH1 in both normal development and disease contexts can provide insights into its role as a cancer marker and facilitator of oncogenic pathways. Consequently, the generation of recombinant EZH1 protein has become a focus for researchers aiming to explore its biochemical properties and to develop novel inhibitor drugs that target its enzymatic function. This research not only contributes to the basic understanding of chromatin biology but also offers prospects for innovative cancer therapies targeting epigenetic regulators like EZH1.
